Literature DB >> 2533530

Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis.

D Troost1, J J van den Oord, J M de Jong, D F Swaab.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating systemic atrophy affecting the upper and lower motor neurons. The etiology is unknown, but one theory of pathogenesis supposes that the motor system is affected by abnormal immune responses. We have studied the prevalence and extent of lymphocytic infiltration, previously reported as a rare finding in the ALS spinal cord. Application of monoclonal antibodies against macrophages, T- and B-cells to spinal cords from 48 ALS patients disclosed a cellular mononuclear infiltrate in 38 specimens (79%), intense enough to be revealed by routine neuropathological techniques in 6 of them (12.5%); the remaining 10 cords (21%) exhibited no infiltrates. Since duration and clinical signs of the preceeding illness were the same in cases with and without infiltrates, we consider it unlikely that such infiltrates are entirely secondary to atrophy of the cord. As Wallerian degeneration is not accompanied by infiltrates of lymphocytes, their presence in the cord tracts of our material throws doubt on the conventional view that tract degeneration in ALS is exclusively Wallerian.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533530

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  36 in total

1.  Amyotrophic Lateral Sclerosis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

2.  From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis.

Authors:  John M Lincecum; Fernando G Vieira; Monica Z Wang; Kenneth Thompson; Gerald S De Zutter; Joshua Kidd; Andrew Moreno; Ricardo Sanchez; Isarelis J Carrion; Beth A Levine; Bashar M Al-Nakhala; Shawn M Sullivan; Alan Gill; Steven Perrin
Journal:  Nat Genet       Date:  2010-03-28       Impact factor: 38.330

3.  Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease.

Authors:  Aaron Burberry; Naoki Suzuki; Jin-Yuan Wang; Rob Moccia; Daniel A Mordes; Morag H Stewart; Satomi Suzuki-Uematsu; Sulagna Ghosh; Ajay Singh; Florian T Merkle; Kathryn Koszka; Quan-Zhen Li; Leonard Zon; Derrick J Rossi; Jennifer J Trowbridge; Luigi D Notarangelo; Kevin Eggan
Journal:  Sci Transl Med       Date:  2016-07-13       Impact factor: 17.956

4.  Inflammatory cells in the peripheral nervous system in motor neuron disease.

Authors:  H Kerkhoff; D Troost; E S Louwerse; M van Dijk; H Veldman; F G Jennekens
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

5.  T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS.

Authors:  Isaac M Chiu; Adam Chen; Yi Zheng; Bela Kosaras; Stefanos A Tsiftsoglou; Timothy K Vartanian; Robert H Brown; Michael C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-07       Impact factor: 11.205

6.  A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis.

Authors:  A Stevens; M Weller; H Wiethölter
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

7.  Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes.

Authors:  Shulamit Naor; Zohar Keren; Tomer Bronshtein; Efrat Goren; Marcelle Machluf; Doron Melamed
Journal:  J Neurol       Date:  2009-03-12       Impact factor: 4.849

8.  Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Rosa Luisa Potenza; Roberta De Simone; Monica Armida; Valentina Mazziotti; Antonella Pèzzola; Patrizia Popoli; Luisa Minghetti
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 9.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

Review 10.  Towards retinoid therapy for Alzheimer's disease.

Authors:  K Shudo; H Fukasawa; M Nakagomi; N Yamagata
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.